Latest Insights on ABBV
The Real Question for the $63 Billion AbbVie-Allergan Acquisition June 25, 2019 Great Stuff
I know my brain doesn’t work quite right. I wouldn’t be writing Great Stuff if it did. Today, I’m left with a burning question on AbbVie’s $63 billion cash and stock acquisition of Allergan. It’s not about the viability of the combined company. Both AbbVie Inc. (NYSE: ABBV) and Allergan PLC (NYSE: AGN) face serious […]
This Biotech Billionaire Loves This Risky Stock April 11, 2018 Technology, Trending
There is a chance you will lose money if you buy today’s stock. But if you’re willing to take on a little risk, I have an opportunity for you that could be very profitable.MEET OUR EXPERTS
Chief Investment Strategist of Money & Markets
Editor of Precision Profits and Apex Alert
Editor of Strategic Fortunes and three elite services
Director of Investment Research
Director of VIP Services
CEO of Banyan Hill
Research Analyst
Editor of Alpha Investor
